KNSA Kiniksa Pharmaceuticals Ltd
Price (delayed)
$22.18
Market cap
$1.61B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.6
Enterprise value
$1.44B
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of
Highlights
Kiniksa Pharmaceuticals's revenue has surged by 57% YoY and by 10% QoQ
KNSA's gross profit has surged by 53% year-on-year and by 9% since the previous quarter
KNSA's quick ratio is down by 21% YoY but it is up by 10% QoQ
KNSA's gross margin is down by 2.3% YoY
Key stats
What are the main financial stats of KNSA
Market
Valuations
Earnings
Shares outstanding
72.64M
Market cap
$1.61B
Enterprise value
$1.44B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.65
Price to sales (P/S)
3.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.4
Revenue
$423.24M
Gross profit
$362.33M
Operating income
-$45.62M
Net income
-$43.19M
EBIT
-$36.15M
EBITDA
-$31.32M
Free cash flow
$25.44M
Per share
Balance sheet
Liquidity
EPS
-$0.6
EPS diluted
-$0.6
Free cash flow per share
$0.36
Book value per share
$6.07
Revenue per share
$5.93
TBVPS
$7.9
Total assets
$580.55M
Total liabilities
$142.12M
Debt
$9.86M
Equity
$438.44M
Working capital
$231.18M
Debt to equity
0.02
Current ratio
3.3
Quick ratio
2.84
Net debt/EBITDA
5.55
Margins
Efficiency
Dividend
EBITDA margin
-7.4%
Gross margin
85.6%
Net margin
-10.2%
Operating margin
-10.8%
Return on assets
-7.9%
Return on equity
-9.9%
Return on invested capital
-11%
Return on capital employed
-7.5%
Return on sales
-8.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KNSA stock price
How has the Kiniksa Pharmaceuticals stock price performed over time
Intraday
-1.42%
1 week
4.28%
1 month
12.88%
1 year
8.41%
YTD
12.13%
QTD
12.13%
Financial performance
How have Kiniksa Pharmaceuticals's revenue and profit performed over time
Revenue
$423.24M
Gross profit
$362.33M
Operating income
-$45.62M
Net income
-$43.19M
Gross margin
85.6%
Net margin
-10.2%
KNSA's operating income has dropped by 81% year-on-year and by 74% since the previous quarter
KNSA's operating margin has dropped by 59% since the previous quarter and by 16% year-on-year
Kiniksa Pharmaceuticals's revenue has surged by 57% YoY and by 10% QoQ
KNSA's gross profit has surged by 53% year-on-year and by 9% since the previous quarter
Growth
What is Kiniksa Pharmaceuticals's growth rate over time
Valuation
What is Kiniksa Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.65
P/S
3.74
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.4
KNSA's price to book (P/B) is 9% higher than its last 4 quarters average of 3.4 and 6% higher than its 5-year quarterly average of 3.5
Kiniksa Pharmaceuticals's revenue has surged by 57% YoY and by 10% QoQ
The stock's price to sales (P/S) is 7% less than its last 4 quarters average of 4.1
Efficiency
How efficient is Kiniksa Pharmaceuticals business performance
KNSA's ROIC has plunged by 124% from the previous quarter and by 112% YoY
The return on sales has dropped by 93% since the previous quarter and by 37% year-on-year
Dividends
What is KNSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KNSA.
Financial health
How did Kiniksa Pharmaceuticals financials performed over time
KNSA's total liabilities has surged by 62% year-on-year and by 20% since the previous quarter
Kiniksa Pharmaceuticals's current ratio has decreased by 24% YoY
The debt is 98% smaller than the equity
The debt to equity has contracted by 33% YoY
The debt has declined by 20% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.